First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
BackgroundThe SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain.MethodsDNA sequencing of 74 c...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bc3ebc5d1a36401a91652476aa999c1a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bc3ebc5d1a36401a91652476aa999c1a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bc3ebc5d1a36401a91652476aa999c1a2021-11-04T07:54:28ZFirst Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study2234-943X10.3389/fonc.2021.744112https://doaj.org/article/bc3ebc5d1a36401a91652476aa999c1a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.744112/fullhttps://doaj.org/toc/2234-943XBackgroundThe SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain.MethodsDNA sequencing of 74 cancer-related genes was performed using FFPE tumor samples in three different laboratories with three different gene panels. A multidisciplinary advisory board prospectively recommended potential targeted treatments. The primary objective was to determine the success of matching somatic DNA alteration to an experimental drug/drug class.ResultsBetween September 2014 and July 2017, 305 patients with ABC from 10 institutions were enrolled. Tumor sequencing was successful in 260 (85.3%) patients. Median age was 54 (29-80); most tumors were hormone receptor-positive/HER2-negative (74%), followed by triple-negative (14.5%) and HER2-positive (11.5%). Ninety-seven (37%) tumor samples analyzed proceeded from metastatic sites. Somatic mutations were identified in 163 (62.7%) patients, mostly in PIK3CA (34%), TP53 (22%), AKT1 (5%), ESR1 (3%), and ERBB2 (3%) genes. Significant enrichment of AKT1 mutation was observed in metastatic versus primary samples (9% vs. 2%; p=0.01). Genome-driven cancer therapy was recommended in 45% (n=116) of successfully screened patients, 11% (n=13) of whom finally received it. Among these patients, 46.2% had a PFS of ≥6 months on matched therapy.ConclusionsAGATA is the first nationwide molecular screening program carried out in Spain and we proved that implementing molecular data in the management of ABC is feasible. Although these results are promising, only 11% of the patients with genome-driven cancer therapy received it.Sonia PernasSonia PernasPatricia VillagrasaAna VivancosMaurizio ScaltritiJordi RodónJordi RodónOctavio BurguésPaolo NuciforoJordi CanesLaia ParéMarta DueñasMarta DueñasMaria VidalMaria VidalMaria VidalJuan Miguel CejalvoJuan Miguel CejalvoJuan Miguel CejalvoAntonia PerellóAntonio Llommbard-CussacJoan DorcaAlvaro MontañoTomás PascualMafalda OliveiraMafalda OliveiraGloria RibasGloria RibasInmaculada RapadoAleix PratAleix PratAleix PratAleix PratEva CiruelosEva CiruelosFrontiers Media S.A.articlebreast cancermolecular geneticDNA sequence analysesPAM50 subtypemolecular targeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
breast cancer molecular genetic DNA sequence analyses PAM50 subtype molecular targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
breast cancer molecular genetic DNA sequence analyses PAM50 subtype molecular targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sonia Pernas Sonia Pernas Patricia Villagrasa Ana Vivancos Maurizio Scaltriti Jordi Rodón Jordi Rodón Octavio Burgués Paolo Nuciforo Jordi Canes Laia Paré Marta Dueñas Marta Dueñas Maria Vidal Maria Vidal Maria Vidal Juan Miguel Cejalvo Juan Miguel Cejalvo Juan Miguel Cejalvo Antonia Perelló Antonio Llommbard-Cussac Joan Dorca Alvaro Montaño Tomás Pascual Mafalda Oliveira Mafalda Oliveira Gloria Ribas Gloria Ribas Inmaculada Rapado Aleix Prat Aleix Prat Aleix Prat Aleix Prat Eva Ciruelos Eva Ciruelos First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| description |
BackgroundThe SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain.MethodsDNA sequencing of 74 cancer-related genes was performed using FFPE tumor samples in three different laboratories with three different gene panels. A multidisciplinary advisory board prospectively recommended potential targeted treatments. The primary objective was to determine the success of matching somatic DNA alteration to an experimental drug/drug class.ResultsBetween September 2014 and July 2017, 305 patients with ABC from 10 institutions were enrolled. Tumor sequencing was successful in 260 (85.3%) patients. Median age was 54 (29-80); most tumors were hormone receptor-positive/HER2-negative (74%), followed by triple-negative (14.5%) and HER2-positive (11.5%). Ninety-seven (37%) tumor samples analyzed proceeded from metastatic sites. Somatic mutations were identified in 163 (62.7%) patients, mostly in PIK3CA (34%), TP53 (22%), AKT1 (5%), ESR1 (3%), and ERBB2 (3%) genes. Significant enrichment of AKT1 mutation was observed in metastatic versus primary samples (9% vs. 2%; p=0.01). Genome-driven cancer therapy was recommended in 45% (n=116) of successfully screened patients, 11% (n=13) of whom finally received it. Among these patients, 46.2% had a PFS of ≥6 months on matched therapy.ConclusionsAGATA is the first nationwide molecular screening program carried out in Spain and we proved that implementing molecular data in the management of ABC is feasible. Although these results are promising, only 11% of the patients with genome-driven cancer therapy received it. |
| format |
article |
| author |
Sonia Pernas Sonia Pernas Patricia Villagrasa Ana Vivancos Maurizio Scaltriti Jordi Rodón Jordi Rodón Octavio Burgués Paolo Nuciforo Jordi Canes Laia Paré Marta Dueñas Marta Dueñas Maria Vidal Maria Vidal Maria Vidal Juan Miguel Cejalvo Juan Miguel Cejalvo Juan Miguel Cejalvo Antonia Perelló Antonio Llommbard-Cussac Joan Dorca Alvaro Montaño Tomás Pascual Mafalda Oliveira Mafalda Oliveira Gloria Ribas Gloria Ribas Inmaculada Rapado Aleix Prat Aleix Prat Aleix Prat Aleix Prat Eva Ciruelos Eva Ciruelos |
| author_facet |
Sonia Pernas Sonia Pernas Patricia Villagrasa Ana Vivancos Maurizio Scaltriti Jordi Rodón Jordi Rodón Octavio Burgués Paolo Nuciforo Jordi Canes Laia Paré Marta Dueñas Marta Dueñas Maria Vidal Maria Vidal Maria Vidal Juan Miguel Cejalvo Juan Miguel Cejalvo Juan Miguel Cejalvo Antonia Perelló Antonio Llommbard-Cussac Joan Dorca Alvaro Montaño Tomás Pascual Mafalda Oliveira Mafalda Oliveira Gloria Ribas Gloria Ribas Inmaculada Rapado Aleix Prat Aleix Prat Aleix Prat Aleix Prat Eva Ciruelos Eva Ciruelos |
| author_sort |
Sonia Pernas |
| title |
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| title_short |
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| title_full |
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| title_fullStr |
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| title_full_unstemmed |
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study |
| title_sort |
first nationwide molecular screening program in spain for patients with advanced breast cancer: results from the agata solti-1301 study |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/bc3ebc5d1a36401a91652476aa999c1a |
| work_keys_str_mv |
AT soniapernas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT soniapernas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT patriciavillagrasa firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT anavivancos firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT maurizioscaltriti firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT jordirodon firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT jordirodon firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT octavioburgues firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT paolonuciforo firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT jordicanes firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT laiapare firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT martaduenas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT martaduenas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT mariavidal firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT mariavidal firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT mariavidal firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT juanmiguelcejalvo firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT juanmiguelcejalvo firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT juanmiguelcejalvo firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT antoniaperello firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT antoniollommbardcussac firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT joandorca firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT alvaromontano firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT tomaspascual firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT mafaldaoliveira firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT mafaldaoliveira firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT gloriaribas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT gloriaribas firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT inmaculadarapado firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT aleixprat firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT aleixprat firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT aleixprat firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT aleixprat firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT evaciruelos firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study AT evaciruelos firstnationwidemolecularscreeningprograminspainforpatientswithadvancedbreastcancerresultsfromtheagatasolti1301study |
| _version_ |
1718445045826191360 |